US ONCOLOGY, INC. | |||||||||
RECONCILIATION OF NET INCOME (LOSS) TO EBITDA AND ADJUSTED EBITDA | |||||||||
(in thousands) | |||||||||
(unaudited) | |||||||||
Three Months Ended | Six Months Ended | ||||||||
June 30,2010 | June 30,2009 | June 30,2010 | June 30,2009 | ||||||
| Net income (loss) | $ (884) | $ (6,651) | $ (88) | $ (4,875) | |||||
| Add back: | |||||||||
| Interest expense, net | 27,672 | 22,484 | 55,117 | 45,106 | |||||
| Income tax provision (benefit) | 1,009 | (1,324) | 914 | 2,280 | |||||
| Depreciation and amortization | 24,399 | 25,172 | 50,153 | 50,270 | |||||
| Amortization of stock compensation | 623 | 268 | 1,269 | 837 | |||||
| Other (income) expense | 387 | (37) | 157 | (37) | |||||
| EBITDA | 53,206 | 39,912 | 107,522 | 93,581 | |||||
| Plus: | |||||||||
| Loss on early extinguishment of debt | - | 22,353 | - | 22,353 | |||||
| Impairment and restructuring charges | 3,269 | 381 | 4,081 | 1,790 | |||||
| Other non-cash charges | 98 | 65 | 196 | 65 | |||||
| Adjusted EBITDA | 56,573 | 62,711 | 111,799 | 117,789 | |||||
| Changes in assets and liabilities | 33,910 | 4,301 | 20,047 | 1,096 | |||||
| Deferred income tax provision (benefit) | (299) | (3,324) | (330) | 2,056 | |||||
| Interest expense, net | (27,672) | (22,484) | (55,117) | (45,106) | |||||
| Income tax benefit (provision) | (1,009) | 1,324 | (914) | (2,280) | |||||
| Net cash provided by operating | |||||||||
activities | $ 61,503 | $ 42,528 | $ 75,485 | $ 73,555 | |||||
